Healthcare Gainers: Agenus Inc (NASDAQ:AGEN), POZEN (NASDAQ:POZN), Aratana Therapeutics Inc (NASDAQ:PETX), EDAP TMS S.A. (ADR) (NASDAQ:EDAP), Applied Genetic Technologies Corp (NASDAQ:AGTC)

Agenus Inc (AGEN) announced phase 2 trial results of its Prophage autologous cancer vaccine for glioblastoma multiforme (GBM) today. The results showed that patients who were administered the vaccine as part of their standard care treatment saw an astonishing 2-year increase in their life spans. The results carry significance because in a majority of cases, the disease tends to kill patients within a year. Agenus Inc (NASDAQ:AGEN) weekly performance is 10.27%. On last trading day company shares ended up $3.80. Analysts mean target price for the company is $7.00. Agenus Inc (NASDAQ:AGEN) distance from 50-day simple moving average is 26.44%.

POZEN Inc. (NASDAQ: POZN) announced that it has resubmitted the New Drug Application (NDA) for PA8140/PA32540 to the U.S. Food and Drug Administration (FDA). In accordance with the regulations, FDA is expected to notify POZEN within 14 days of receipt of the NDA whether or not the submission will be accepted, and if accepted, what the new PDUFA date will be. The FDA will determine whether a two month or six month review is necessary. Issues raised during an audit of the manufacturing facility producing an active ingredient used in the manufacture of the products were the only deficiencies noted in the Complete Response Letter (CRL) POZEN received on April 25, 2014. Final agreement on the draft product labeling is also pending.POZEN Inc. (NASDAQ:POZN) shares advanced 7.83% in last trading session and ended the day on $9.23. POZN its return on assets is -13.60%. POZEN Inc. (NASDAQ:POZN) quarterly performance is 10.94%.

Aratana Therapeutics Inc (NASDAQ:PETX) , a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. ADXS -0.95% for the treatment of canine osteosarcoma and other cancers. While the USDA has no specific obligation to respond within a prescribed timeframe, Aratana anticipates that responses from the USDA to the filing will occur over the next 12 to 18 months. Aratana Therapeutics Inc (NASDAQ:PETX) shares moved up 6.02% in last trading session and was closed at $17.26, while trading in range of $16.25-$17.32. Aratana Therapeutics Inc (NASDAQ:PETX) year to date performance is -9.63%.

EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that the U.S. Food and Drug Administration (FDA) concluded its routine inspection of EDAP’s manufacturing site with no findings nor issuance of Form 483 observations.EDAP TMS S.A. (ADR) (NASDAQ:EDAP) ended the last trading day at $5.82. Company weekly volatility is calculated as 9.03% and price to cash ratio as 13.75. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) showed a positive weekly performance of 35.66%.

Applied Genetic Technologies (Nasdaq: AGTC) announced that it has appointed David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to the company’s Board of Directors.Applied Genetic Technologies Corp (NASDAQ:AGTC) weekly performance is -21.17%. On last trading day company shares ended up $24.16. Analysts mean target price for the company is $29.00. Applied Genetic Technologies Corp (NASDAQ:AGTC) distance from 50-day simple moving average is 30.01%.